Clinical Trial Update: A Study of Ixekizumab (LY2439821) in TNF Inhibitor Experienced Participants With Radiographic Axial Spondyloarthritis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating ixekizumab in TNF inhibitor–experienced participants with radiographic axial spondyloarthritis has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Radiographic Axial Spondyloarthritis
• Spondyloarthritis

Drugs mentioned

• Ixekizumab (ixekizumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Spondyloarthritis | Phase 3 | Status: COMPLETED | Results posted: 2019-10-30